Abstract:e16532 Background: To observe the effect of chronic disease condition on the therapeutic effect and survival period of cancer patients treated with UMIPIC. Methods: 2594 cancer patients in our hospital from January 2011 to December 2015 who received UMIPIC for the study objects. 576 cases with chronic diseases, 2018 without chronic disease, 840 with lung cancer, 712 with esophageal cancer, 254 with liver cancer, 108 with pancreatic cancer, 93 with gastric cancer, 587 with other cancers. They signed the consent for treatment, evaluated the efficacy, followed up to the clinical effect, adverse reactions, survival data of patients. Results: The side effects of the chronic disease patients with cancer after UMIPIC therapy is fever at 26.56%, pain at 15.10%, the second was hemoglobin reduction 16.48%, leucopenia 5.27%, liver function damage 2.67%, thrombocytopenia 2.45%, nausea 2.26%, vomiting 1.39%, neurotoxicity and hair loss of less than 0.20%, while cancer patients without chronic disease after UMIPIC therapy, side effect is fever at 32.37%, pain at14.87%, hemoglobin reduction 13.26%, leucopenia 6.09%, nausea 2.73%, thrombocytopenia 2.6% 3%, liver function damage 1.77%, vomiting 1.73%, kidney function damage 0.89%, neurotoxicity and hair loss were lower than 0.20%; there is only fever difference in the two groups (P < 0.05).There was no significant difference in other adverse reactions. This may be due to the immunity of normal patients was stronger than that of chronic patients. It was found that the clinical benefit rate of 90.91% in patients with chronic diseases was significantly lower than 93.44% in patients without chronic diseases (P = 0.021); after follow-up, we found that the mean survival time of patients with chronic diseases was 22.149 months, median survival time was 10.300 months, while median survival time of patients without chronic diseases was 22.940 months, median survival time was 11.200 months, and the survival rates of patients without chronic diseases for 1, 2, 3 and 5-year were 48.94%, 29.97%, 25.19%, and 25.18% respectively, it is significantly higher than those of patients with chronic diseases (43.19%, 22.33%, 18.37% and 16.04%) (P<0.05). Conclusions: The survival time and survival rate of the patients without chronic diseases are higher than those of the patients with chronic diseases. The side effects of chronic diseases on the patients with cancer treated with UMIPIC are not significant different except for fever. The patients with chronic diseases can safely receive UMIPIC treatment.

The Effect of Hapten on the Clinical Efficacy and Survival of Patients with Liver Cancer Treated by UMIPIC.

Hapten-enhanced Overall Survival Time in Advanced Hepatocellular Carcinoma by Ultro-Minimum Incision Personalized Intratumoral Chemoimmunotherapy

Hapten-enhanced Therapeutic Effect in Advanced Stages of Lung Cancer by Ultra-Minimum Incision Personalized Intratumoral Chemoimmunotherapy Therapy

Hapten Enhanced Personalized Chemoimmunotherapy By Ultra-Minimum Incision Personalized Intratumoral Chemoimmuno-Therapy: Umipic-Therapy In Advanced Pancreatic Cancer

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

The Effect of Adoptive Immunotherapy after Percutaneous Microwave Ablation in Recurrent Hepatocellular Carcinoma Patients with Hepatitis B: A Preliminary Study

Observation of Clinical Efficacy and Survival of Lung Cancer Patients with UMIPIC Combined with Low-Dose Chemotherapy.

The Effect of Chronic Diseases on the Clinical Effect and Survival Period of Patients with Solid Tumor Treated with UMIPIC.

Effect of Dendritic Cell-Based Immunotherapy on Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Microwave ablation and combined with adoptive immunotherapy for hepatocellular carcinoma

Short-Term Effect Of Combined Therapy With Jinlong Capsule ((Sic)) And Transcatheter Arterial Chemoembolization On Patients With Primary Hepatic Carcinoma And Its Influence On Serum Osteopontin Expression

Adjuvant Immunotherapy Improves Recurrence-Free and Overall Survival Following Surgical Resection for Intermediate/advanced Hepatocellular Carcinoma a Multicenter Propensity Matching Analysis

The Efficacy Of A New High-Intensity Focused Ultrasound Therapy For Metastatic Pancreatic Cancer

Multiple Courses of Immunotherapy with Different Immune Cell Types for Patients with Hepatocellular Carcinoma after Microwave Ablation.

Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study

Efficacy and Safety of PD‐1 Inhibitor Combined with Antiangiogenic Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients

Survival outcomes with adjuvant immunotherapy after hepatic resection in patients with intermediate/advanced (BCLC stage B/C) hepatocellular carcinoma: Insights from a propensity-matched multicenter study.

Primary Screening of Antitumor Immunoadjuvants Combined with Heat Shock Fusion Protein

Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review

Comparing Clinical Outcomes Between PD-1 and PD-L1 Inhibitors Plus Bevacizumab Combined with Hepatic Arterial Interventional Therapies in Unresectable Hepatocellular Carcinoma: A Single-Center Real-World Study.